Press releases

25 Nov 2014

Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform

read more
06 May 2014

Synthon and MAB Discovery Sign Multi-Target Antibody Discovery Agreement

read more
02 Apr 2014

Synthon’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC

read more
14 Jan 2014

Synthon Biopharmaceuticals ramping up for initiation of Phase I study with its frontrunner ADC SYD985

read more